Perrigo Company plc (PRGO)
Market Cap | 3.70B |
Revenue (ttm) | 4.39B |
Net Income (ttm) | -159.60M |
Shares Out | 136.43M |
EPS (ttm) | -1.17 |
PE Ratio | n/a |
Forward PE | 8.70 |
Dividend | $1.10 (4.07%) |
Ex-Dividend Date | Nov 29, 2024 |
Volume | 1,232,011 |
Open | 27.26 |
Previous Close | 27.24 |
Day's Range | 26.80 - 27.30 |
52-Week Range | 23.89 - 34.60 |
Beta | 0.48 |
Analysts | Buy |
Price Target | 37.00 (+36.28%) |
Earnings Date | Nov 6, 2024 |
About PRGO
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health pr... [Read more]
Financial Performance
In 2023, Perrigo Company's revenue was $4.66 billion, an increase of 4.58% compared to the previous year's $4.45 billion. Losses were -$12.70 million, -90.97% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PRGO stock is "Buy." The 12-month stock price forecast is $37.0, which is an increase of 36.28% from the latest price.
News
Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Perrigo's long-term growth is driven by strategic initiatives like Project Energize, aiming for $140-$170 million in annualized savings by 2026. The company's reinvestments in leadership and IT, addin...
Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript
Perrigo Company plc (NYSE:PRGO) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor ...
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perri...
Perrigo Announces Quarterly Dividend
DUBLIN , Nov. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly divid...
Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024
DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial resu...
WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health
Opill® and Collier will hit the road to talk to women about their reproductive health options. GRAND RAPIDS, Mich.
Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio
DUBLIN , Sept. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start®1 and Dr. Brown'...
PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY
DUBLIN , Sept. 17, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the closing of a registered public offering by Perrigo Finance Unlimited Company, ...
PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY
DUBLIN , Sept. 12, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the pricing of a registered public offering by Perrigo Finance Unlimited Company, ...
Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary
Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Cons...
Perrigo to Attend the Piper Sandler Growth Frontiers Conference
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduar...
Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer
DUBLIN , Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice P...
Perrigo is voluntarily recalling 16,500 cans of baby formula because of high levels of Vitamin D
Perrigo Co. Plc PRGO, +0.54% said Friday it's voluntarily recalling 16,500 cans of store brand Premium Infant Formula with iron milk-based powder because of levels of Vitamin D that exceed permitted l...
Perrigo recalls 16,500 cans of its infant formula
Perrigo has initiated a voluntary recall of three lots within one batch, or 16,500 cans, of its infant formula sold at H-E-B Grocery Company and CVS , a regulatory filing showed on Friday.
Perrigo Company plc (PRGO) Q2 2024 Earnings Call Transcript
Perrigo Company plc (NYSE:PRGO) Q2 2024 Earnings Conference Call August 2, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - ...
Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations
Delivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enh...
Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference
DUBLIN , July 31, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduar...
Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024
DUBLIN , July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial res...
Perrigo Completes Divestment of HRA Pharma Rare Diseases Business
DUBLIN , July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it has completed the previo...
Notice of Proposed Settlement and Plan of Allocation Involving Purchasers of Perrigo Common Stock from April 21, 2015 through May 2, 2017 and Owners of Perrigo Common Stock as of November 12, 2015
SEATTLE, June 24, 2024 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference
DUBLIN , May 28, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduard...
Perrigo Company plc (PRGO) Q1 2024 Earnings Call Transcript
Perrigo Company plc (NYSE:PRGO) Q1 2024 Earnings Call Transcript May 7, 2024 8:30 AM ET Company Participants Brad Joseph - VP, Global IR Patrick Lockwood-Taylor - President and CEO Eduardo Bezerra - ...
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of In...
Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business
Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN , May 7, 2024 /PRNe...
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Mill...